Molecular diagnosis in lung diseases

Frontiers in Bioscience - Landmark

Volumn 20, Issue 4, 2015, Pages 644-688

  Calabrese, Fiorella ^a   Lunardi, Francesca ^a   Popper, Helmut ^b  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Infection; Lung; Lung cancer; Molecular techniques; Review; Targeted therapy

Indexed keywords

GENETICS; HUMAN; LUNG DISEASES; LUNG NEOPLASMS; MICROBIOLOGY; MOLECULAR DIAGNOSIS; PATHOLOGY;

HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES;

EID: 84918830689     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4329     Document Type: Review

References (262)

1. W.W. Grody, R.A. Gatti, F. Naeim: Diagnostic molecular pathology. Mod Pathol 2, 553-568 (1989)
2. J.A. Fairley, K. Gilmour, K. Walsh: Making the most of pathological specimens: molecular diagnosis in formalin-fixed, paraffin embedded tissue. Curr Drug Targets 13, 1475-1487 (2012) DOI: 10.2174/138945012803530125
3. M. Dietel, K. Jöhrens, M. Laffert, M. Hummel, H. Bläker, B.M. Müller, A. Lehmann, C. Denkert, F.L. Heppner, A. Koch, C. Sers, I. Anagnostopoulos: Predictive molecular pathology and its role in targeted cancer therapy: a review focusing on clinical relevance. Cancer Gene Ther 20, 211-221 (2013) DOI: 10.1038/cgt.2013.13
4. J. Bhatnagar, T. Jones, D.M. Blau, W.J. Shieh, C.D. Paddock, C. Drew, A.M. Denison, D.C. Rollin, M. Patel, S.R. Zaki: Localization of pandemic 2009 H1N1 influenza A virus RNA in lung and lymph nodes of fatal influenza cases by in situ hybridization: New insights on virus replication and pathogenesis. J Clin Virol 56, 232-237 (2013) DOI: 10.1016/j.jcv.2012.11.014
5. M.A. Innes, D.H. Gelfand, J.J. Sninsky, T.J. White: PCR Protocols, A Guide to Methods and Application. Eds Academic, San Diego, CA (1990)
6. S. Paireder, B. Werner, J. Bailer, W. Werther, E. Schmid, B. Patzak, M. Cichna-Mark: Comparison of protocols for DNA extraction from long-term preserved formalin fixed tissues. Anal Biochem 439, 152-160 (2013) DOI: 10.1016/j.ab.2013.04.006
7. G. Stanta, S. Bonin: RNA quantitative analysis from fixed and paraffin-embedded tissues: membrane hybridization and capillary electrophoresis. Biotechniques 24, 271-276 (1998)
8. M. Cronin, M. Pho, D. Dutta, J.C. Stephans, S. Shak, M.C. Kiefer, J.M. Esteban, J.B. Baker: Measurement of Gene Expression in Archival Paraffin-Embedded Tissues. Am J Pathol 164, 35-42 (2004) DOI: 10.1016/S0002-9440(10)63093-3
9. J. Cheval, V. Sauvage, L. Frangeul, L. Dacheux, G. Guigon, N. Dumey, K. Pariente, C. Rousseaux, F. Dorange, N. Berthet, S, Brisse, I. Moszer, H. Bourhy, C.J. Manuguerra, M. Lecuit, A. Burguiere, V. Caro, M. Eloit: Evaluation of high-throughput sequencing for identifying known and unknown viruses in biological samples. J Clin Microbiol 49:3268-3275 (2011) DOI: 10.1128/JCM.00850-11
10. L.J. Van't Veer, H. Dai, M.J. van de Vijver, Y.D. He, A.A. Hart, M. Mao, H.L. Peterse, K. van der Kooy, M.J. Marton, A.T. Witteveen, G.J. Schreiber, R.M. Kerkhoven, C. Roberts, P.S. Linsley, R. Bernards, S.H. Friend. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002) DOI: 10.1038/415530a
11. D. Wang, L. Coscoy, M. Zylberberg, P.C. Avila, H.A. Boushey, D. Ganem, J.L. DeRisi: Microarray-based detection and genotyping of viral pathogens. Proc Natl Acad Sci USA 99,15687-15692 (2002) DOI: 10.1073/pnas.242579699
12. J.D. Fox: Nucleic acid amplification tests for detection of respiratory viruses. J Clin Virol 40, S15-S23 (2007) DOI: 10.1016/S1386-6532(07)70005-7
13. S. Yang, R.E. Rothman: PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis 4, 337-348 (2004) DOI: 10.1016/S1473-3099(04)01044-8
14. D. Klein: Quantification using real-time PCR technology: applications and limitations. Trends Mol Med 8, 257-260 (2002) DOI: 10.1016/S1471-4914(02)02355-9
15. S. Yang, R.E. Rothman: PCR-based diagnostics for infectious diseases: uses, limitations, and future applications in acute-care settings. Lancet Infect Dis 4, 337-348 (2004) DOI: 10.1016/S1473-3099(04)01044-8
16. S. Pillet, M. Lardeux, J. Dina, F. Grattard, P. Verhoeven, J. Le Goff, A. Vabret, B. Pozzetto: Comparative evaluation of six commercialized multiplex PCR kits for the diagnosis of respiratory infections. PLoS One 8, e72174 (2013) DOI: 10.1371/journal.pone.0072174
17. L.T. Franc¸a, E. Carrilho, T.B. Kist: A review of DNA sequencing techniques. Q Rev Biophys 35, 169-200 (2002) DOI: 10.1017/S0033583502003797
18. A. Altimari, D. de Biase, G. De Maglio, E. Gruppioni, E. Capizzi, A. Degiovanni, A. D'Errico, A. Pession, S. Pizzolitto, M. Fiorentino, G. Tallini: 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples. Onco Targets Ther 6:1057-1064 (2013)
19. J.M. Rizzo, M.J. Buck: Key principles and clinical applications of "Next-generation"DNA sequencing. Cancer Prev Res (Phila) 5, 887-900 (2012) DOI: 10.1158/1940-6207.CAPR-11-0432
20. D. de Biase, M. Visani, U. Malapelle, F. Simonato, V. Cesari, C. Bellevicine, A. Pession, G. Troncone, A. Fassina, G. Tallini: Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy) PLoS One 8, e83607 (2013) DOI: 10.1371/journal.pone.0083607
21. J.A. Fishman, R.H. Rubin: Infection in organ-transplant recipients. N Engl J Med 338, 1741-1751 (1998) DOI: 10.1056/NEJM199806113382407
22. K.D. Sims, E.A. Blumberg: Common infections in the lung transplant recipient. Clin Chest Med 32, 327-341 (2011) DOI: 10.1016/j.ccm.2011.02.010
23. I.G. Sia, J.A. Wilson, C.M. Groettum, M.J. Espy, T.F. Smith, C.V. PayA: Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 181, 717-720 (2000) DOI: 10.1086/315242
24. W.L. Drew: Ganciclovir resistance: a matter of time and titer. Lancet 356, 609-610 (2000) DOI: 10.1016/S0140-6736(00)02597-6
25. S.M. Bhorade, C. Sandesara, E.R. Garrity, W.T. Vigneswaran, L. Norwick, S. Alkan, A.N. Husain, M.A. McCabe, V. Yeldandi: Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 20, 928-934 (2001) DOI: 10.1016/S1053-2498(01)00283-2
26. J.L. Sanchez, R.M. Kruger, S. Paranjothi, E.P. Trulock, J.P. Lynch, C. Hicks, W.D. Shannon, G.A. Storch: Relationship of cytomegalovirus viral load in blood to pneumonitis in lung transplant recipients. Transplantation 72: 733-735 (2001) DOI: 10.1097/00007890-200108270-00030
27. E. Arbustini, M. Grasso, M. Diegoli, E. Percivalle, P. Grossi, M. Bramerio, C. Campana, C. Goggi, A. Gavazzi, M. Vigano: Histopathologic and molecular profile of human cytomegalovirus infections in patients with heart transplants. Am J Clin Pathol 98: 205-213 (1992)
28. D.Y. Lu, J. Qian, K.A. Easley, S.M. Waldrop, C. Cohen: Automated in situ hybridization and immunohistochemistry for cytomegalovirus detection in paraffin-embedded tissue sections. Appl Immunohistochem Mol Morphol 17, 158-164 (2009) DOI: 10.1097/ PAI.0b013e318185d1b5
29. L. Wilkens, M. Werner, M. Nolte, R.V. Wasielewski, W. Verhagen, J. Flik, J. Klempnauer, A. Georgii: Influence of formalin fixation on the detection of cytomegalovirus by polymerase chain reaction in immunocompromised patients and correlation to in situ hybridization, immunohistochemistry, and serological data. Diagn Mol Pathol 3, 156-162 (1994) DOI: 10.1097/00019606-199409000-00004
30. G.C. Riise, R. Andersson, T. Bergstrom, A. Lundmark, F.N. Nilsson, S. Olofsson: Quantification of cytomegalovirus DNA in BAL fluid: a longitudinal study in lung transplant recipients. Chest 118, 1653-1660 (2000) DOI: 10.1378/chest.118.6.1653
31. C. Liesnard, L. De Wit, S. Motte, F. Brancart, J. Content: Rapid diagnosis of cytomegalovirus lung infection by DNA amplification in bronchoalveolar lavages. Mol Cell Probes 8, 273-283 (1994) DOI: 10.1006/mcpr.1994.1039
32. G.P. Westall, A. Michaelides, T.J. Williams, G.I. Snell, T.C. Kotsimbos: Human Cytomegalovirus Load in Plasma and Bronchoalveolar Lavage Fluid: A Longitudinal Study of Lung Transplant Recipients. J Infect Dis 190, 1076-1083 (2004) DOI: 10.1086/422327
33. C.B. Hall. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344, 1917-1928 (2001) DOI: 10.1056/NEJM200106213442507
34. E. Malcolm, E. Arruda, F.G. Hayden, L. Kaiser: Clinical features of patients with acute respiratory illness and rhinovirus in their bronchoalveolar lavages. J Clin Virol 21: 9-16 (2001) DOI: 10.1016/S1386-6532(00)00180-3
35. N.G. Papadopoulos, P.J. Bates, P.G. Bardin, A. Papi, S.H. Leir, D.J. Fraenkel, J. Meyer, P.M. Lackie, G. Sanderson, S.T. Holgate, S.L. Johnston: Rhinoviruses infect the lower airways. J Infect Dis 181, 1875-1884 (2000) DOI: 10.1086/315513
36. M.G. Ison, F.G Hayden, L. Kaiser, L. Corey, M. Boeckh: Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 36:1139-1143 (2003) DOI: 10.1086/374340
37. L. Kaiser, J.D. Aubert, J.C. Pache, C. Deffernez, T. Rochat, J. Garbino, W. Wunderli, P. Meylan, S. Yerly, L. Perrin, I. Letovanec, L. Nicod, C. Tapparel, P.M. Soccal: Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med 174, 1392-1399 (2006) DOI: 10.1164/rccm.200604-489OC
38. O.A. EL Zammar; A. Katzenstein: Pathological diagnosis of granulomatous lung disease: a review. Histopathology 50, 289-310 (2007) DOI: 10.1111/j.1365-2559.2006.02546.x
39. G. Cserni: Auramine fluorescence for acid-fast bacilli in formalin-fixed paraffin-embedded tissues. Am J Clin Pathol 103, 114 (1995)
40. D.E. Minnikin, S.M. Minnikin, J.H. Parlett, M. Goodfellow, M. Magnusson: Mycolic acid patterns of some species of Mycobacterium. Arch Microbiol 139, 225-231 (1984) DOI: 10.1007/BF00402005
41. P. Seiler, T. Ulrichs, S. Bandermann, L. Pradl, S. Jörg, V. Krenn, L. Morawietz, S.H. Kaufmann, P. Aichele: Cell-wall alterations as an attribute of Mycobacterium tuberculosis in latent infection. J Infect Dis 188, 1326-1331 (2003) DOI: 10.1086/378563
42. I.K.Neonakis, Z. Gitti, E. Krambovitis, D.A. Spandidos: Molecular diagnostic tools in mycobacteriology. J Microbiol Methods 75, 1-11 (2008) DOI: 10.1016/j.mimet.2008.05.023
43. A.R. Zink, A.G. Nerlich: Molecular strain identification of the M. tuberculosis complex in archival tissue samples. J Clin Pathol 57, 1185-1192 (2004) DOI: 10.1136/jcp.2003.015719
44. T. Goldmann, E. Vollmer: PCR-based diagnosis of mycobacteria: use and pitfalls of formalin-fixed, paraffin-embedded specimens. Eur J Pathol 8,4-03 (2002)
45. C. Schewe, T. Goldmann, M. Grosser, A. Zink, K. Schlüns, S. Pahl, T. Ulrichs, S.H. Kaufmann, A. Nerlich, G.B. Baretton, M. Dietel, E. Vollmer, I. Petersen: Interlaboratory validation of PCR-based detection of Mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissues. Virchows Arch 447, 573-585 (2005) DOI: 10.1007/s00428-005-1233-3
46. N. Escobar-Escamilla, J.E. Ramírez-González, M. González-Villa, P. Torres-Mazadiego, A. Mandujano-Martínez, C. Barrón-Rivera, C.E. Bäcker, D.E. Fragoso-Fonseca, H. Olivera-Díaz, P. Alcántara-Pérez, A. Hernández-Solís, R. Cícero-Sabido, I.A. Cortés-Ortíz: hsp65 Phylogenetic Assay for Molecular Diagnosis of Nontuberculous Mycobacteria Isolated in Mexico. Arch Med Res 45, 90-97 (2014) DOI: 10.1016/j.arcmed.2013.12.004
47. H. Fukunaga, T. Murakami, T. Gondo, K. Sugi, T. Ishihara: Sensitivity of acid-fast staining for Mycobacterium tuberculosis in formalin-fixed tissue. Am J Respir Crit Care Med 166, 994-997 (2002) DOI: 10.1164/rccm.2111028
48. R. Hernández-Pando, M. Jeyanathan, G. Mengistu, D. Aguilar, H. Orozco, M. Harboe, G.A. Rook, G. Bjune: Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet. 356 : 2133-2138 (2000) DOI: 10.1016/S0140-6736(00)03493-0
49. N.V. Salian, J.A. Rish, K.D. Eisenach, M.D. Cave, J. H. Bates: Polymerase chain reaction to detect Mycobacterium tuberculosis in histologic specimens. Am J Respir Crit Care Med 158, 1150-1155 (1998) DOI: 10.1164/ajrccm.158.4.9802034
50. N. Singh, D.L. Paterson: Aspergillus infections in transplant recipients. Clin Microbiol Rev 18: 44 (2005) DOI: 10.1128/CMR.18.1.44-69.2005
51. R. Scerif, B.H. Segal: Pulmonary aspergillosis: clinical presentation, diagnostic tests, management and complications. Curr Opin Pulm Med 16, 242-250 (2010)
52. J.L. Hsu, S.J. Ruoss, N.D. Bower, M. Lin, M. Holodniy, D.A. Stevens: Diagnosing invasive fungal disease in critically ill patients. Crit Rev Microbiol 37, 277-312 (2011) DOI: 10.3109/1040841X.2011.581223
53. M. Cuenca-Estrella, Y. Meije, C. Diaz-Pedroche, A. Gomez-Lopez, M.J. Buitrago, L. Bernal-Martinez, C. Grande, R.S. Juan, M. Lizasoain, J.L. Rodriguez-Tudela, J.M. Aguado: Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J Clin Microbiol 47, 379-384 (2009) DOI: 10.1128/JCM.01716-08
54. W.H. Wheat, C.D. Cool, Y. Morimoto, P.R. Rai, C.H. Kirkpatrick, B.A. Lindenbaum, C.A. Bates, M.C. Ellison, A.E. Serls, K.K. Brown, J.M. Routes: Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med 202, 479-484 (2005) DOI: 10.1084/jem.20050381
55. K.A. Staskus, R.Sun, G. Miller, P. Racz, A. Jaslowski, C. Metroka, H. Brett-Smith, A.T. Haase: Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol 73, 4181-4187 (1999)
56. M. Tamm, F. Reichenberger, C.E. McGandy, A. Stalder, A. Tietz, P. Dalquen, A.P. Perruchoud, G. Cathomas: Diagnosis of Pulmonary Kaposi's Sarcoma by Detection of Human Herpes Virus 8 in Bronchoalveolar Lavage. Am J Resp Crit Care Med 157, 458-463 (1998) DOI: 10.1164/ajrccm.157.2.9707068
57. B. Tarp, S. Jensen-Fangel, R. Dahl, N. Obel: Herpesvirus type 1-8 in BAL fluid from HIV-1-infected patients with suspected pneumonia and from healthy individuals. Eur Respir J 18, 146-150 (2001) DOI: 10.1183/09031936.01.00090601
58. G.P. Cosgrove, M.I. Schwartz: Lymphocy toplasmic infiltrations of the lung. In: Interstitial Lung Disease. Eds: Schwarz MI, King TE Jr. People's Medical Publishing House, Hamilton, USA (2011)
59. W.G. Morice, P.J. Kurtin, J.L. Myers: Expression of cytolytic lymphocyte-associated antigens in pulmonary lymphomatoid granulomatosis. Am J Clin Pathol 118, 391 (2002) DOI: 10.1309/PMR7-7XLY-F10U-4V1Q
60. M. Izadi, S. Taheri: Significance of in situ hybridization results for EBV-encoded RNA in post-transplantation lymphoproliferative disorder setting: report from the PTLD. Int Survey. Ann Transplant 15, 102-109 (2010)
61. E.S. Jaffe, W.H. Wilson: Lymphomatoid granulomatosis: Pathogenesis, pathology and clinical implications. Cancer Surv 30, 233 (1997)
62. I.P. Neuringer: Postransplant lympho proliferative disorder after lung transplantation. Clin Dev Immunol 2013, 430209 (2013) DOI: 10.1155/2013/430209
63. P.M. Kaan, R.G. Hegele, S. Hayashi, J.C. Hogg: Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia. Thorax 52,12-16 (1997) DOI: 10.1136/thx.52.1.12
64. W. Wockel, G. Hofler, H. H. Popper and A. Morresi: Lymphoepithelioma-like carcinoma of the lung. Pathol Res Pract 191, 1170-1174 (1995) DOI: 10.1016/S0344-0338(11)80665-5
65. Y. L. Chang, C. T. Wu, J. Y. Shih and Y. C. Lee: New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas. Am J Surg Pathol 26, 715-723 (2002) DOI: 10.1097/00000478-200206000-00004
66. H. H. Popper, Y. el-Shabrawi, W. Wockel, G. Hofler, L. Kenner, F. M. Juttner-Smolle and M. G. Pongratz: Prognostic importance of human papilloma virus typing in squamous cell papilloma of the bronchus: comparison of in situ hybridization and the polymerase chain reaction. Hum Pathol 25, 1191-1197 (1994) DOI: 10.1016/0046-8177(94)90036-1
67. S. Solinas-Toldo, M. Durst and P. Lichter: Specific chromosomal imbalances in human papillomavirus-transfected cells during progression toward immortality. Proc Natl Acad Sci U S A 94, 3854-3859 (1997) DOI: 10.1073/pnas.94.8.3854
68. S. M. Lele, A. M. Pou, K. Ventura, Z. Gatalica and D. Payne: Molecular events in the progression of recurrent respiratory papillomatosis to carcinoma. Arch Pathol Lab Med 126, 1184-1188 (2002)
69. M. Paraskeva, M. Bailey, B.J. Levvey, A.P. Griffiths, T.C. Kotsimbos, T.P. Williams, G. Snell, G. Westall: Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 11:2190-2196 (2011) DOI: 10.1111/j.1600-6143.2011.03663.x
70. C. Neurohr, P. Huppmann, H. Leuchte, M. Schwaiblmair, I. Bittmann, G. Jaeger, R. Hatz, L. Frey, P. Uberfuhr, B. Reichart, J. Behr; Munich Lung Transplant Group: Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 5, 2982-2991 (2005) DOI: 10.1111/j.1600-6143.2005.01103.x
71. C. Costa, L. Delsedimide, P. Solidoro, A. Curtoni, M. Bergallo, D. Libertucci, S. Baldi, M. Rinaldi, R. Cavallo: Herpesviruses detection by quantitative real-time polymerase chain reaction in bronchoalveolar lavage and transbronchial biopsy in lung transplant: viral infections and histopathological correlation. Transplant Proc 42,1270 (2010) DOI: 10.1016/j.transproceed.2010.03.086
72. D.L. Vu, P.O. Bridevaux, J.D. Aubert, P.M. Soccal, L. Kaiser:. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant 11:1071-1078 (2011) DOI: 10.1111/j.1600-6143.2011.03490.x
73. M.Y. Armanios, J.J. Chen, J.D. Cogan, J.K. Alder, R.G. Ingersoll, C. Markin, W.E. Lawson, M. Xie, I. Vulto, J.A. Phillips 3rd, P.M. Lansdorp, C.W. Greider, J.E. Loyd: Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356:1317-1326 (2007) DOI: 10.1056/NEJMoa066157
74. A.Q. Thomas, K. Lane, J. Phillips 3rd, M. Prince, C. Markin, M. Speer, D.A. Schwartz, R. Gaddipati, A. Marney, J. Johnson, R. Roberts, J. Haines, M. Stahlman, J.E. Loyd: Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am J Respir Crit Care Med 165, 1322-1328 (2002) DOI: 10.1164/rccm.200112-123OC
75. M.A. Seibold, A.L. Wise, M.C. Speer, M.P. Steele, K.K. Brown, J.E. Loyd, T.E. Fingerlin, W. Zhang, G. Gudmundsson, S.D. Groshong, C.M. Evans, S. Garantziotis, K.B. Adler, B.F. Dickey, R.M. du Bois, I.V. Yang, A. Herron, D. Kervitsky, J.L. Talbert, C. Markin, J. Park, A.L. Crews, S.H. Slifer, S. Auerbach, M.G. Roy, J. Lin, C.E. Hennessy, M.I. Schwarz, D.A. Schwartz: A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med 364:1503-1512 (2011) DOI: 10.1056/NEJMoa1013660
76. A.L. Peljto, Y. Zhang, T.E. Fingerlin, S.F. Ma, J.G. Garcia, T.J. Richards, L.J. Silveira, K.O. Lindell, M.P. Steele, J.E. Loyd, K.F. Gibson, M.A. Seibold, K.K. Brown, J.L. Talbert, C. Markin, K. Kossen, S.D. Seiwert, E. Murphy, I. Noth, M.I. Schwarz, N. Kaminski, D.A. Schwartz: Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:2232-2239 (2013) DOI: 10.1001/jama.2013.5827
77. T.E.King Jr, A. Pardo, M. Selman: Idiopathic pulmonary fibrosis. Lancet 378:1949-1961 (2011) DOI: 10.1016/S0140-6736(11)60052-4
78. J.P. Stewart, J.J. Egan, A.J. Ross, B.G. Kelly, S.S. Lok, P.S. Hasleton, A.A.Woodcock: The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 159:1336-1341 (1999) DOI: 10.1164/ajrccm.159.4.9807077
79. F. Calabrese, A. Kipar, F. Lunardi, E. Balestro, E. Perissinotto, E. Rossi, N. Nannini, G. Marulli, J.P. Stewart, F. Rea: Herpes virus infection is associated with vascular remodeling and pulmonary hypertension in idiopathic pulmonary fibrosis. PLoS One 8, e55715 (2013) DOI: 10.1371/journal.pone.0055715
80. K. Tsukamoto, H. Hayakawa, A. Sato, K. Chida, H. Nakamura, K. Miura K: Involvement of Epstein-Barr virus latent membrane protein 1 in disease progression in patients with idiopathic pulmonary fibrosis. Thorax 55, 958-961 (2000) DOI: 10.1136/thorax.55.11.958
81. M. Decaussin, H. Sartelet, C. Robert, D. Moro, C. Claraz, C. Brambilla and E. Brambilla: Expression of vascular endothelial growth factor (VEGF) and its two receptors (VEGF-R1-Flt1 and VEGF-R2-Flk1/KDR) in non-small cell lung carcinomas (NSCLCs): correlation with angiogenesis and survival. J Pathol 188, 369-377 (1999) DOI:10.1002/(SICI)1096-9896(199908)188:4〈369::AID-PATH 381〉3.0. CO;2-X DOI:10.1002/(SICI)1096-9896(199 908)188:4〈369::AID-PATH381〉3.3.CO; 2-O
82. A. A. Adjei: Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5, S51-55 (2004) DOI: 10.3816/CLC.2004.s.003
83. M. I. Koukourakis, A. Giatromanolaki, E. Sivridis, K. C. Gatter and A. L. Harris: Pyruvate dehydrogenase and pyruvate dehydrogenase kinase expression in non small cell lung cancer and tumor-associated stroma. Neoplasia 7, 1-6 (2005) DOI: 10.1593/neo.04373
84. R. L. Keith, Y. E. Miller, R. M. Gemmill, H. A. Drabkin, E. C. Dempsey, T. C. Kennedy, S. Prindiville and W. A. Franklin: Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer. Clin Cancer Res 6, 1616-1625 (2000)
85. M. Takahama, M. Tsutsumi, T. Tsujiuchi, K. Nezu, K. Kushibe, S. Taniguchi, Y. Kotake and Y. Konishi: Enhanced expression of Tie2, its ligand angiopoietin-1, vascular endothelial growth factor, and CD31 in human non-small cell lung carcinomas. Clin Cancer Res 5, 2506-2510 (1999)
86. A. M. Maeshima, N. Tochigi, A. Yoshida, H. Asamura, K. Tsuta and H. Tsuda: Clinicopathologic analysis of multiple (five or more) atypical adenomatous hyperplasias (AAHs) of the lung: evidence for the AAH-adenocarcinoma sequence. J Thorac Oncol 5, 466-471 (2010) DOI: 10.1097/JTO.0b013e3181ce3b73
87. N. Guedj, A. Couvelard, G. Arcangeli, S. Dubois, G. Thabut, G. Leseche, M. Fournier, C. Degott and O. Groussard: Angiogenesis and extracellular matrix remodelling in bronchioloalveolar carcinomas: distinctive patterns in mucinous and non-mucinous tumours. Histopathology 44, 251-256 (2004) DOI: 10.1111/j.1365-2559.2004.01803.x
88. H. Kojima, N. Shijubo, G. Yamada, S. Ichimiya, S. Abe, M. Satoh and N. Sato: Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer 104, 1668-1677 (2005) DOI: 10.1002/cncr.21366
89. C. J. Langer and R. B. Natale: The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin Oncol 32, S23-29 (2005) DOI: 10.1053/j.seminoncol.2005.10.005
90. M. Mae, T. P. O'Connor and R. G. Crystal: Gene transfer of the vascular endothelial growth factor receptor flt-1 suppresses pulmonary metastasis associated with lung growth. Am J Respir Cell Mol Biol 33, 629-635 (2005) DOI: 10.1165/rcmb.2005-0092OC
91. M. D. Hellmann, J. E. Chaft, V. Rusch, M. S. Ginsberg, D. J. Finley, M. G. Kris, K. A. Price, C. G. Azzoli, M. G. Fury, G. J. Riely, L. M. Krug, R. J. Downey, M. S. Bains, C. S. Sima, N. Rizk, W. D. Travis, N. A. Rizvi and P. K. Paik: Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. Cancer Chemother Pharmacol 72, 453-461 (2013) DOI: 10.1007/s00280-013-2219-5
92. T. Kajita, Y. Ohta, K. Kimura, M. Tamura, Y. Tanaka, Y. Tsunezuka, M. Oda, T. Sasaki and G. Watanabe: The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br J Cancer 85, 255-260 (2001) DOI: 10.1054/bjoc.2001.1882
93. T. Niki, S. Iba, T. Yamada, Y. Matsuno, B. Enholm and S. Hirohashi: Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma. J Pathol 193, 450-457 (2001) DOI: 10.1002/path.828
94. M. Arinaga, T. Noguchi, S. Takeno, M. Chujo, T. Miura and Y. Uchida: Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with nonsmall cell lung carcinoma. Cancer 97, 457-464 (2003) DOI: 10.1002/cncr.11073
95. Y. Li, M. N. Wang, H. Li, K. D. King, R. Bassi, H. Sun, A. Santiago, A. T. Hooper, P. Bohlen and D. J. Hicklin: Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J Exp Med 195, 1575-1584 (2002) DOI: 10.1084/jem.20020072
96. A. Abdollahi, K. E. Lipson, A. Sckell, H. Zieher, F. Klenke, D. Poerschke, A. Roth, X. Han, M. Krix, M. Bischof, P. Hahnfeldt, H. J. Grone, J. Debus, L. Hlatky and P. E. Huber: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 63, 8890-8898 (2003)
97. J. Lin, A. S. Lalani, T. C. Harding, M. Gonzalez, W. W. Wu, B. Luan, G. H. Tu, K. Koprivnikar, M. J. VanRoey, Y. He, K. Alitalo and K. Jooss: Inhibition of lymphogenous metastasis using adenoassociated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65, 6901-6909 (2005) DOI: 10.1158/0008-5472.CAN-05-0408
98. O. Takahashi, R. Komaki, P. D. Smith, J. M. Jurgensmeier, A. Ryan, B. N. Bekele, Wistuba, II, J. J. Jacoby, M. V. Korshunova, A. Biernacka, B. Erez, K. Hosho, R. S. Herbst and M. S. O'Reilly: Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res 18, 1641-1654 (2012) DOI: 10.1158/1078-0432.CCR-11-2324
99. B. Das, H. Yeger, R. Tsuchida, R. Torkin, M. F. Gee, P. S. Thorner, M. Shibuya, D. Malkin and S. Baruchel: A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma. Cancer Res 65, 7267-7675 (2005) DOI: 10.1158/0008-5472.CAN-04-4575
100. S. R. Boreddy, R. P. Sahu and S. K. Srivastava: Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-alpha/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS ONE 6, e25799 (2011) DOI: 10.1371/journal.pone.0025799
101. A. Goyal, C. Poluzzi, C. D. Willis, J. Smythies, A. Shellard, T. Neill and R. V. Iozzo: Endorepellin affects angiogenesis by antagonizing diverse vascular endothelial growth factor receptor 2 (VEGFR2)-evoked signaling pathways: transcriptional repression of hypoxia-inducible factor 1alpha and VEGFA and concurrent inhibition of nuclear factor of activated T cell 1 (NFAT1) activation. J Biol Chem 287, 43543-4356 (2012) DOI: 10.1074/jbc.M112.401786
102. K. A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. Andre, V. Haddad, E. Taranchon, M. Filipits, R. Pirker, H. H. Popper, R. Stahel, L. Sabatier, J. P. Pignon, T. Tursz, T. Le Chevalier and J. C. Soria: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355, 983-991 (2006) DOI: 10.1056/NEJMoa060570
103. R. G. Zinner, S. Novello, G. Peng, R. Herbst, C. Obasaju and G. Scagliotti: Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials. Clin Lung Cancer 11, 126-131 (2010) DOI: 10.3816/CLC.2010.n.017
104. E. Giovannetti, C. Lemos, C. Tekle, K. Smid, S. Nannizzi, J. A. Rodriguez, S. Ricciardi, R. Danesi, G. Giaccone and G. J. Peters: Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 73, 1290-1300 (2008) DOI: 10.1124/mol.107.042382
105. S. Grant, L. Qiao and P. Dent: Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front Biosci 7, 376-389 (2002) DOI: 10.2741/grant
106. C. V. Rajadurai, S. Havrylov, K. Zaoui, R. Vaillancourt, M. Stuible, M. Naujokas, D. Zuo, M. L. Tremblay and M. Park: Met receptor tyrosine kinase signals through a cortactin-Gab1 scaffold complex, to mediate invadopodia. J Cell Sci 125, 2940-2953 (2012) DOI: 10.1242/jcs.100834
107. J. Kim, S. Ahn, R. Guo and Y. Daaka: Regulation of epidermal growth factor receptor internalization by G protein-coupled receptors. Biochemistry 42, 2887-2894 (2003) DOI: 10.1021/bi026942t
108. M. Nomura, H. Shigematsu, L. Li, M. Suzuki, T. Takahashi, P. Estess, M. Siegelman, Z. Feng, H. Kato, A. Marchetti, J. W. Shay, M. R. Spitz, Wistuba, II, J. D. Minna and A. F. Gazdar: Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med 4, e125 (2007) DOI: 10.1371/journal.pmed.0040125
109. S. Yano, W. Wang, Q. Li, K. Matsumoto, H. Sakurama, T. Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe and S. Sone: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 68(22), 9479-9487 (2008) DOI: 10.1158/0008-5472.CAN-08-1643
110. R. H. Palmer, E. Vernersson, C. Grabbe and B. Hallberg: Anaplastic lymphoma kinase: signalling in development and disease. Biochem J 420, 345-361 (2009) DOI: 10.1042/BJ20090387
111. D. W. Wong, E. L. Leung, S. K. Wong, V. P. Tin, A. D. Sihoe, L. C. Cheng, J. S. Au, L. P. Chung and M. P. Wong: A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 117, 2709-18 (2011) DOI: 10.1002/cncr.25843
112. B. Zhang, X. Pan, G. P. Cobb and T. A. Anderson: microRNAs as oncogenes and tumor suppressors. Dev Biol 302, 1-12 (2007) DOI: 10.1016/j.ydbio.2006.08.028
113. M. S. Kumar, J. Lu, K. L. Mercer, T. R. Golub and T. Jacks: Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39, 673-677 (2007) DOI: 10.1038/ng2003
114. J.-C. Bourdon, K. Fernandes, F. Murray-Zmijewski, G. Liu, A. Diot, D. P. Xirodimas, M. K. Saville and D. P. Lane: p53 isoforms can regulate p53 transcriptional activity. Genes Dev 19, 2122-2137 (2005) DOI: 10.1101/gad.1339905
115. B. Vogelstein and K. W. Kinzler: p53 function and dysfunction. Cell 70, 523-526 (1992) DOI: 10.1016/0092-8674(92)90421-8
116. K. Husgafvel-Pursiainen, P. Boffetta, A. Kannio, F. Nyberg, G. Pershagen, A. Mukeria, V. Constantinescu, C. Fortes and S. Benhamou: p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Cancer Res 60, 2906-2911 (2000)
117. S. N. Rodin and A. S. Rodin: Human lung cancer and p53: the interplay between mutagenesis and selection. Proc Natl Acad Sci U S A 97, 12244-12249 (2000) DOI: 10.1073/pnas.180320897
118. M. Sanchez-Cespedes, S. A. Ahrendt, S. Piantadosi, R. Rosell, M. Monzo, L. Wu, W. H. Westra, S. C. Yang, J. Jen and D. Sidransky: Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61, 1309-1313 (2001)
119. S. Zienolddiny, D. Ryberg, M. O. Arab, V. Skaug and A. Haugen: Loss of heterozygosity is related to p53 mutations and smoking in lung cancer. Br J Cancer 84, 226-231 (2001) DOI: 10.1054/bjoc.2000.1528
120. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas and J. Bartek: DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005) DOI: 10.1038/nature03482
121. M. Hollstein, D. Sidransky, B. Vogelstein and C. C. Harris: p53 mutations in human cancers. Science 253, 49-53 (1991) DOI: 10.1126/science.1905840
122. T. Takahashi, D. D'Amico, I. Chiba, D. L. Buchhagen and J. D. Minna: Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer. J. Clin. Invest 86, 363-369 (1990) DOI: 10.1172/JCI114710
123. R. Iggo, K. Gatter, J. Bartek, D. Lane and A. L. Harris: Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet, 335, 675-679 (1990) DOI: 10.1016/0140-6736(90)90801-B
124. J. Yokota and T. Kohno: Molecular footprints of human lung cancer progression. Cancer Sci 95, 197-204 (2004) DOI: 10.1111/j.1349-7006.2004.tb02203.x
125. J. Yokota, M. Nishioka, M. Tani and T. Kohno: Genetic alterations responsible for metastatic phenotypes of lung cancer cells. Clin Exp Metastasis 20, 189-193 (2003) DOI: 10.1023/A:1022978932215
126. D. L. Gibbons, W. Lin, C. J. Creighton, S. Zheng, D. Berel, Y. Yang, M. G. Raso, D. D. Liu, Wistuba, II, G. Lozano and J. M. Kurie: Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma. PLoS ONE 4, e5401 (2009) DOI: 10.1371/journal.pone.0005401
127. J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F. J. Kaye, N. Lindeman, T. J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. J. Eck, W. R. Sellers, B. E. Johnson and M. Meyerson: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004) DOI: 10.1126/science.1099314
128. R. Sordella, D. W. Bell, D. A. Haber and J. Settleman: Gefitinib-sensitizing EGFR mutations in lung cancer activate antiapoptotic pathways. Science 305, 1163-1167 (2004) DOI: 10.1126/science.1101637
129. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman and D. A. Haber: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350, 2129-2139 (2004) DOI: 10.1056/NEJMoa040938
130. T. Isobe, R. S. Herbst and A. Onn: Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 32, 315-328 (2005) DOI: 10.1053/j.seminoncol.2005.02.016
131. H. A. Yu and W. Pao: Targeted therapies: Afatinib - new therapy option for EGFR-mutant lung cancer. Nat Rev Clin Oncol 10, 551-552 (2013) DOI: 10.1038/nrclinonc.2013.154
132. M. P. Morelli, T. Cascone, T. Troiani, C. Tuccillo, R. Bianco, N. Normanno, M. Romano, B. M. Veneziani, G. Fontanini, S. G. Eckhardt, S. De Pacido, G. Tortora and F. Ciardiello: Anti-tumor activity of the combination of cetuximab, an anti- EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. J Cell Physiol 208, 344-353 (2006) DOI: 10.1002/jcp.20666
133. R. Pirker, J. R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. de Marinis, W. E. Eberhardt, L. Paz-Ares, S. Storkel, K. M. Schumacher, A. von Heydebreck, I. Celik and K. J. O'Byrne: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13, 33-42 (2012) DOI: 10.1016/S1470-2045(11)70318-7
134. J. M. Siegfried, A. T. Gillespie, R. Mera, T. J. Casey, P. Keohavong, J. R. Testa and J. D. Hunt: Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 6, 841-847 (1997)
135. M. Wislez, N. Fujimoto, J. G. Izzo, A. E. Hanna, D. D. Cody, R. R. Langley, H. Tang, M. D. Burdick, M. Sato, J. D. Minna, L. Mao, I. Wistuba, R. M. Strieter and J. M. Kurie: High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 66, 4198-4207 (2006) DOI: 10.1158/0008-5472.CAN-05-3842
136. M. D. To, C. E. Wong, A. N. Karnezis, R. Del Rosario, R. Di Lauro and A. Balmain: Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet 40, 1240-1244 (2008) DOI: 10.1038/ng.211
137. Y. Zhou, W. M. Rideout, 3rd, T. Zi, A. Bressel, S. Reddypalli, R. Rancourt, J. K. Woo, J. W. Horner, L. Chin, M. I. Chiu, M. Bosenberg, T. Jacks, S. C. Clark, R. A. Depinho, M. O. Robinson and J. Heyer: Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas. Nat Biotechnol 28, 71-78 (2010) DOI: 10.1038/nbt.1595
138. M. Musteanu, L. Blaas, R. Zenz, J. Svinka, T. Hoffmann, B. Grabner, D. Schramek, H. P. Kantner, M. Muller, T. Kolbe, T. Rulicke, R. Moriggl, L. Kenner, D. Stoiber, J. M. Penninger, H. Popper, E. Casanova and R. Eferl: A mouse model to identify cooperating signaling pathways in cancer. Nat Methods 9, 897-900 (2012) DOI: 10.1038/nmeth.2130
139. C. Li, R. Fang, Y. Sun, X. Han, F. Li, B. Gao, A. J. Iafrate, X. Y. Liu, W. Pao, H. Chen and H. Ji: Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS ONE 6, e28204 (2011) DOI: 10.1371/journal.pone.0028204
140. B. Gao, Y. Sun, J. Zhang, Y. Ren, R. Fang, X. Han, L. Shen, X. Y. Liu, W. Pao, H. Chen and H. Ji: Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas. J Thorac Oncol 5, 1130-1135 (2010) DOI: 10.1097/JTO.0b013e3181e05016
141. S. Ren, P. Kuang, L. Zheng, C. Su, J. Li, B. Li, X. Chen, Y. Wang, V. Kimcurran, L. Liu, Q. Hu, J. Zhang, L. Tang and C. Zhou: Analysis of driver mutations in female non-smoker asian patients with pulmonary adenocarcinoma. Cell Biochem Biophys 64, 155-160 (2012) DOI: 10.1007/s12013-012-9384-8
142. G. Scagliotti, R. A. Stahel, R. Rosell, N. Thatcher and J. C. Soria: ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 48, 961-973 (2012) DOI: 10.1016/j.ejca.2012.02.001
143. K. Ikeda, H. Nomori, T. Mori, J. Sasaki and T. Kobayashi: Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer. Ann Thorac Surg 85, 1430-1432 (2008) DOI: 10.1016/j.athoracsur.2007.10.012
144. M. Nakao, J. Yoshida, K. Goto, G. Ishii, A. Kawase, K. Aokage, T. Hishida, M. Nishimura and K. Nagai: Long-term outcomes of 50 cases of limited-resection trial for pulmonary ground-glass opacity nodules. J Thorac Oncol 7, 1563-1566 (2012) DOI: 10.1097/JTO.0b013e3182641b5c
145. S. Zhang, F. Wang, J. Keats, X. Zhu, Y. Ning, S. D. Wardwell, L. Moran, Q. K. Mohemmad, R. Anjum, Y. Wang, N. I. Narasimhan, D. Dalgarno, W. C. Shakespeare, J. J. Miret, T. Clackson and V. M. Rivera: Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des 78, 999-1005 (2011) DOI: 10.1111/j.1747-0285.2011.01239.x
146. P. A. Janne and M. Meyerson: ROS1 rearrangements in lung cancer: a new genomic subset of lung adenocarcinoma. J Clin Oncol 30, 878-879 (2012) DOI: 10.1200/JCO.2011.39.4197
147. Y. Suehara, M. Arcila, L. Wang, A. Hasanovic, D. Ang, T. Ito, Y. Kimura, A. Drilon, U. Guha, V. Rusch, M. G. Kris, M. F. Zakowski, N. Rizvi, R. Khanin and M. Ladanyi: Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 18(24), 6599-6608 (2012) DOI: 10.1158/1078-0432.CCR-12-0838
148. V. M. Rimkunas, K. E. Crosby, D. Li, Y. Hu, M. E. Kelly, T. L. Gu, J. S. Mack, M. R. Silver, X. Zhou and H. Haack: Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res 18, 4449-4457 (2012) DOI: 10.1158/1078-0432.CCR-11-3351
149. K. Bergethon, A. T. Shaw, S. H. Ou, R. Katayama, C. M. Lovly, N. T. McDonald, P. P. Massion, C. Siwak-Tapp, A. Gonzalez, R. Fang, E. J. Mark, J. M. Batten, H. Chen, K. D. Wilner, E. L. Kwak, J. W. Clark, D. P. Carbone, H. Ji, J. A. Engelman, M. Mino-Kenudson, W. Pao and A. J. Iafrate: ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30, 863-870 (2012) DOI: 10.1200/JCO.2011.35.6345
150. Y. Arai, Y. Totoki, H. Takahashi, H. Nakamura, N. Hama, T. Kohno, K. Tsuta, A. Yoshida, H. Asamura, M. Mutoh, F. Hosoda, H. Tsuda and T. Shibata: Mouse model for ROS1-rearranged lung cancer. PLoS ONE 8, e56010 (2013) DOI: 10.1371/journal.pone.0056010
151. L. P. Chin, R. A. Soo, R. Soong and S. H. Ou: Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer. J Thorac Oncol 7, 1625-1630 (2012) DOI: 10.1097/JTO.0b013e31826baf83
152. T. Komiya, A. Thomas, S. Khozin, A. Rajan, Y. Wang and G. Giaccone: Response to crizotinib in ROS1-rearranged non-small-cell lung cancer. J Clin Oncol 30(27), 3425-6; author reply 3426 (2012) DOI: 10.1200/JCO.2012.42.4556
153. H. Yasuda, L. L. de Figueiredo-Pontes, S. Kobayashi and D. B. Costa: Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7, 1086-1090 (2012) DOI: 10.1097/JTO.0b013e3182570919
154. R. Wang, H. Hu, Y. Pan, Y. Li, T. Ye, C. Li, X. Luo, L. Wang, H. Li, Y. Zhang, F. Li, Y. Lu, Q. Lu, J. Xu, D. Garfield, L. Shen, H. Ji, W. Pao, Y. Sun and H. Chen: RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30, 4352-4359 (2012) DOI: 10.1200/JCO.2012.44.1477
155. K. Takeuchi, M. Soda, Y. Togashi, R. Suzuki, S. Sakata, S. Hatano, R. Asaka, W. Hamanaka, H. Ninomiya, H. Uehara, Y. Lim Choi, Y. Satoh, S. Okumura, K. Nakagawa, H. Mano and Y. Ishikawa: RET, ROS1 and ALK fusions in lung cancer. Nat Med 18, 378-381 (2012) DOI: 10.1038/nm.2658
156. Y. S. Ju, W. C. Lee, J. Y. Shin, S. Lee, T. Bleazard, J. K. Won, Y. T. Kim, J. I. Kim, J. H. Kang and J. S. Seo: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 22, 436-445 (2012) DOI: 10.1101/gr.133645.111
157. J. Bean, C. Brennan, J. Y. Shih, G. Riely, A. Viale, L. Wang, D. Chitale, N. Motoi, J. Szoke, S. Broderick, M. Balak, W. C. Chang, C. J. Yu, A. Gazdar, H. Pass, V. Rusch, W. Gerald, S. F. Huang, P. C. Yang, V. Miller, M. Ladanyi, C. H. Yang and W. Pao: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A, 104, 20932-20937 (2007) DOI: 10.1073/pnas.0710370104
158. D. R. Spigel, T. J. Ervin, R. A. Ramlau, D. B. Daniel, J. H. Goldschmidt, Jr., G. R. Blumenschein, Jr., M. J. Krzakowski, G. Robinet, B. Godbert, F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, W. Yu, J. Zha, R. L. Yauch, P. H. Patel, S. C. Phan and A. C. Peterson: Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 31, 4105-4114 (2013) DOI: 10.1200/JCO.2012.47.4189
159. A. Villar-Garea and M. Esteller: Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 112, 171-178 (2004) DOI: 10.1002/ijc.20372
160. N. Sengupta and E. Seto: Regulation of histone deacetylase activities. J Cell Biochem 93, 57-67 (2004) DOI: 10.1002/jcb.20179
161. T. A. Melhuish, C. M. Gallo and D. Wotton: TGIF2 interacts with histone deacetylase 1 and represses transcription. J Biol Chem 276, 32109-32114 (2001) DOI: 10.1074/jbc.M103377200
162. C. Beisel, A. Imhof, J. Greene, E. Kremmer and F. Sauer: Histone methylation by the Drosophila epigenetic transcriptional regulator Ash1. Nature 419(6909), 857-862 (2002) DOI: 10.1038/nature01126
163. H. Sasaki, S. Moriyama, Y. Nakashima, Y. Kobayashi, M. Kiriyama, I. Fukai, Y. Yamakawa and Y. Fujii: Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer 46, 171-8 (2004) DOI: 10.1016/j.lungcan.2004.03.021
164. M. C. Chen, C. H. Chen, J. C. Wang, A. C. Tsai, J. P. Liou, S. L. Pan and C. M. Teng: The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Cell Death Dis 4, e810 (2013) DOI: 10.1038/cddis.2013.330
165. S. K. Pal, R. A. Figlin and K. Reckamp: Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 9, 1931-1944 (2010) DOI: 10.1158/1535-7163.MCT-10-0239
166. S. J. An, Z. H. Chen, J. Su, X. C. Zhang, W. Z. Zhong, J. J. Yang, Q. Zhou, X. N. Yang, L. Huang, J. L. Guan, Q. Nie, H. H. Yan, T. S. Mok and Y. L. Wu: Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 7, e40109 (2012) DOI: 10.1371/journal.pone.0040109
167. J. S. Seo, Y. S. Ju, W. C. Lee, J. Y. Shin, J. K. Lee, T. Bleazard, J. Lee, Y. J. Jung, J. O. Kim, S. B. Yu, J. Kim, E. R. Lee, C. H. Kang, I. K. Park, H. Rhee, S. H. Lee, J. I. Kim, J. H. Kang and Y. T. Kim: The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 22, 2109-2119 (2012) DOI: 10.1101/gr.145144.112
168. R. A. Moorehead, O. H. Sanchez, R. M. Baldwin and R. Khokha: Transgenic overexpression of IGF-II induces spontaneous lung tumors: a model for human lung adenocarcinoma. Oncogene 22, 853-857 (2003) DOI: 10.1038/sj.onc.1206188
169. T. G. Gharib, G. Chen, C. C. Huang, D. E. Misek, M. D. Iannettoni, S. M. Hanash, M. B. Orringer and D. G. Beer: Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas. Clin Lung Cancer 5, 307-312 (2004) DOI: 10.3816/CLC.2004.n.011
170. Y. Chen, M. Pacyna-Gengelbach, F. Ye, T. Knosel, P. Lund, N. Deutschmann, K. Schluns, W. F. Kotb, C. Sers, H. Yasumoto, T. Usui and I. Petersen: Insulin-like growth factor binding protein-related protein 1 (IGFBP-rP1) has potential tumour-suppressive activity in human lung cancer. J Pathol 211, 431-438 (2007) DOI: 10.1002/path.2132
171. F. Morgillo, W. Y. Kim, E. S. Kim, F. Ciardiello, W. K. Hong and H. Y. Lee: Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 13, 2795-2803 (2007) DOI: 10.1158/1078-0432.CCR-06-2077
172. A. Gualberto and D. D. Karp: Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer. Clin Lung Cancer 10, 273-80 (2009) DOI: 10.3816/CLC.2009.n.038
173. C. Gridelli, A. Rossi, M. A. Bareschino, C. Schettino, P. C. Sacco and P. Maione: The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer. Expert Opin Investig Drugs 19, 631-639 (2010) DOI: 10.1517/13543781003767434
174. J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schottle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansen, D. Rauh, I. Baessmann, J. Altmuller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sanger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nurnberg, S. Perner and R. K. Thomas: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2, 62-93 (2010) DOI: 10.1126/scitranslmed.3001451
175. A. Dutt, A. H. Ramos, P. S. Hammerman, C. Mermel, J. Cho, T. Sharifnia, A. Chande, K. E. Tanaka, N. Stransky, H. Greulich, N. S. Gray and M. Meyerson: Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer. PLoS ONE 6, e20351 (2011) DOI: 10.1371/journal.pone.0020351
176. Z. W. Cai, Y. Zhang, R. M. Borzilleri, L. Qian, S. Barbosa, D. Wei, X. Zheng, L. Wu, J. Fan, Z. Shi, B. S. Wautlet, S. Mortillo, R. Jeyaseelan, Sr., D. W. Kukral, A. Kamath, P. Marathe, C. D'Arienzo, G. Derbin, J. C. Barrish, J. A. Robl, J. T. Hunt, L. J. Lombardo, J. Fargnoli and R. S. Bhide: Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo(2,1-f) (1,2,4)triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215) J Med Chem 51, 1976-1980 (2008) DOI: 10.1021/jm7013309
177. S. A. Antoniu and M. R. Kolb: Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis. IDrugs 13, 332-345 (2010)
178. M. Nakatsugawa, A. Takahashi, Y. Hirohashi, T. Torigoe, S. Inoda, M. Murase, H. Asanuma, Y. Tamura, R. Morita, Y. Michifuri, T. Kondo, T. Hasegawa, H. Takahashi and N. Sato: SOX2 is overexpressed in stem-like cells of human lung adenocarcinoma and augments the tumorigenicity. Lab Invest 91, 1796-804 (2011) DOI: 10.1038/labinvest.2011.140
179. K. Mantripragada and H. Khurshid: Targeting genomic alterations in squamous cell lung cancer. Front Oncol 3, 195 (2013) DOI: 10.3389/fonc.2013.00195
180. L. Li, H. Yu, X. Wang, J. Zeng, D. Li, J. Lu, C. Wang, J. Wang, J. Wei, M. Jiang and B. Mo: Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res 32, 28 (2013) DOI: 10.1186/1756-9966-32-28
181. V. D. Martinez, K. L. Thu, E. A. Vucic, R. Hubaux, M. Adonis, L. Gil, C. MacAulay, S. Lam and W. L. Lam: Whole-genome sequencing analysis identifies a distinctive mutational spectrum in an arsenic-related lung tumor. J Thorac Oncol 8, 1451-1455 (2013) DOI: 10.1097/JTO.0b013e3182a4dd8e
182. C. M. Rudin, S. Durinck, E. W. Stawiski, J. T. Poirier, Z. Modrusan, D. S. Shames, E. A. Bergbower, Y. Guan, J. Shin, J. Guillory, C. S. Rivers, C. K. Foo, D. Bhatt, J. Stinson, F. Gnad, P. M. Haverty, R. Gentleman, S. Chaudhuri, V. Janakiraman, B. S. Jaiswal, C. Parikh, W. Yuan, Z. Zhang, H. Koeppen, T. D. Wu, H. M. Stern, R. L. Yauch, K. E. Huffman, D. D. Paskulin, P. B. Illei, M. Varella-Garcia, A. F. Gazdar, F. J. de Sauvage, R. Bourgon, J. D. Minna, M. V. Brock and S. Seshagiri: Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44, 1111-1116 (2012) DOI: 10.1038/ng.2405
183. Y. Chen, Y. Huang, J. Chen, S. Wang and J. Zhou: The prognostic value of SOX2 expression in non-small cell lung cancer: a meta-analysis. PLoS ONE 8, e71140 (2013) DOI: 10.1371/journal.pone.0071140
184. K. A. Olaussen, J. C. Soria, L. Morat, A. Martin, L. Sabatier, J. F. Morere, D. Khayat and J. P. Spano: Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res 23, 4885-4890 (2003)
185. D. D. Sarbassov, D. A. Guertin, S. M. Ali and D. M. Sabatini: Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005) DOI: 10.1126/science.1106148
186. F. Zhang, X. Zhang, M. Li, P. Chen, B. Zhang, H. Guo, W. Cao, X. Wei, X. Cao, X. Hao and N. Zhang: mTOR complex component Rictor interacts with PKCzeta and regulates cancer cell metastasis. Cancer Res 70, 9360-9370 (2010) DOI: 10.1158/0008-5472.CAN-10-0207
187. D. D. Sarbassov, S. M. Ali, S. Sengupta, J. H. Sheen, P. P. Hsu, A. F. Bagley, A. L. Markhard and D. M. Sabatini: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22, 159-168 (2006) DOI: 10.1016/j.molcel.2006.03.029
188. J. T. Fong, R. J. Jacobs, D. N. Moravec, S. B. Uppada, G. M. Botting, M. Nlend and N. Puri: Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer. PLoS ONE 8, e78398 (2013) DOI: 10.1371/journal.pone.0078398
189. D. Ishikawa, S. Takeuchi, T. Nakagawa, T. Sano, J. Nakade, S. Nanjo, T. Yamada, H. Ebi, L. Zhao, K. Yasumoto, T. Nakamura, K. Matsumoto, H. Kagamu, H. Yoshizawa and S. Yano: mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS ONE 8, e62104 (2013) DOI: 10.1371/journal.pone.0062104
190. E. Pros, S. Lantuejoul, L. Sanchez-Verde, S. D. Castillo, E. Bonastre, A. Suarez-Gauthier, E. Conde, J. C. Cigudosa, F. Lopez-Rios, J. Torres-Lanzas, J. Castellvi, S. Ramon y Cajal, E. Brambilla and M. Sanchez-Cespedes: Determining the profiles and parameters for gene amplification testing of growth factor receptors in lung cancer. Int J Cancer 133, 898-907 (2013) DOI: 10.1002/ijc.28090
191. U. McDermott, R. Y. Ames, A. J. Iafrate, S. Maheswaran, H. Stubbs, P. Greninger, K. McCutcheon, R. Milano, A. Tam, D. Y. Lee, L. Lucien, B. W. Brannigan, L. E. Ulkus, X. J. Ma, M. G. Erlander, D. A. Haber, S. V. Sharma and J. Settleman: Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors. Cancer Res 69, 3937-3946 (2009) DOI: 10.1158/0008-5472.CAN-08-4327
192. M. Hou, Y. Morishita, T. Iljima, Y. Inadome, K. Mase, Y. Dai and M. Noguchi: DNA methylation and expression of p16(INK4A) gene in pulmonary adenocarcinoma and anthracosis in background lung. Int J Cancer 84, 609-613 (1999) DOI: 10.1002/(SICI)1097-0215 (19991222)84:6〈609::AID-IJC12〉3.0.CO;2-Q DOI: 10.1002/(SICI)1097-0215 (19991222)84:6〈609::AID-IJC12〉3.3.CO;2-H
193. H. Osada and T. Takahashi: Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 21, 7421-7434 (2002) DOI: 10.1038/sj.onc.1205802
194. S. Toyooka, K. O. Toyooka, R. Maruyama, A. K. Virmani, L. Girard, K. Miyajima, K. Harada, Y. Ariyoshi, T. Takahashi, K. Sugio, E. Brambilla, M. Gilcrease, J. D. Minna and A. F. Gazdar: DNA methylation profiles of lung tumors. Mol Cancer Ther 1, 61-67 (2001)
195. S. Licciulli, J. L. Avila, L. Hanlon, S. Troutman, M. Cesaroni, S. Kota, B. Keith, M. C. Simon, E. Pure, F. Radtke, A. J. Capobianco and J. L. Kissil: Notch1 is required for Kras-induced lung adenocarcinoma and controls tumor cell survival via p53. Cancer Res 73, 5974-5984 (2013) DOI: 10.1158/0008-5472.CAN-13-1384
196. A. Bernheim, S. Toujani, P. Saulnier, T. Robert, O. Casiraghi, P. Validire, S. Temam, P. Menard, P. Dessen and P. Fouret: High-resolution array comparative genomic hybridization analysis of human bronchial and salivary adenoid cystic carcinoma. Lab Invest 88, 464-473 (2008) DOI: 10.1038/labinvest.2008.18
197. J. Osanyingbemi-Obidi, I. Dobromilskaya, P. B. Illei, C. L. Hann and C. M. Rudin: Notch signaling contributes to lung cancer clonogenic capacity in vitro but may be circumvented in tumorigenesis in vivo. Mol Cancer Res 9, 1746-1754 (2011) DOI: 10.1158/1541-7786.MCR-11-0286
198. T. Saito, C. Y. Sasaki, L. J. Rezanka, P. Ghosh and D. L. Longo: p52-Independent nuclear translocation of RelB promotes LPS-induced attachment. Biochem Biophys Res Commun 391, 235-241 (2010) DOI: 10.1016/j.bbrc.2009.11.039
199. G. Rossi, M. C. Mengoli, A. Cavazza, D. Nicoli, M. Barbareschi, C. Cantaloni, M. Papotti, A. Tironi, P. Graziano, M. Paci, A. Stefani, M. Migaldi, G. Sartori and G. Pelosi: Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch 464, 61-68 (2014) DOI: 10.1007/s00428-013-1501-6
200. M. S. Tsao, N. Liu, J. R. Chen, J. Pappas, J. Ho, C. To, J. Viallet, M. Park and H. Zhu: Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers. Lung Cancer 20, 1-16 (1998) DOI: 10.1016/S0169-5002(98)00007-5
201. M. Strazisar, V. Mlakar, T. Rott and D. Glavac: Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma. Cancer Invest 27, 407-416 (2009) DOI: 10.1080/07357900802427919
202. B. C. Mak and R. S. Yeung: The tuberous sclerosis complex genes in tumor development. Cancer Invest 22, 588-603 (2004) DOI: 10.1081/CNV-200027144
203. Y. L. Chang, C. T. Wu, J. Y. Shih and Y. C. Lee: Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas. Cancer Sci 102, 282-287 (2011) DOI: 10.1111/j.1349-7006.2010.01768.x
204. K. Uchida, A. Kojima, N. Morokawa, O. Tanabe, C. Anzai, M. Kawakami, Y. Eto and K. Yoshimura: Expression of progastrin-releasing peptide and gastrin-releasing peptide receptor mRNA transcripts in tumor cells of patients with small cell lung cancer. J Cancer Res Clin Oncol 128, 633-640 (2002) DOI: 10.1007/s00432-002-0392-8
205. N. A. Levin, P. M. Brzoska, M. L. Warnock, J. W. Gray and M. F. Christman: Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosomes Cancer 13, 175-185 (1995) DOI: 10.1002/gcc.2870130307
206. R. Ullmann, A. Schwendel, H. Klemen, G. Wolf, I. Petersen and H. H. Popper: Unbalanced chromosomal aberrations in neuroendocrine lung tumors as detected by comparative genomic hybridization. Hum Pathol 29, 1145-1149 (1998) DOI: 10.1016/S0046-8177(98)90428-2
207. J. W. Harbour, S. L. Lai, J. Whang-Peng, A. F. Gazdar, J. D. Minna and F. J. Kaye: Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science 241, 353-7 (1988) DOI: 10.1126/science.2838909
208. S. L. Lai, H. Brauch, T. Knutsen, B. E. Johnson, M. M. Nau, T. Mitsudomi, C. M. Tsai, J. Whang-Peng, B. Zbar, F. J. Kaye and et al.: Molecular genetic characterization of neuroendocrine lung cancer cell lines. Anticancer Res 15, 225-232 (1995)
209. Wistuba, II, A. F. Gazdar and J. D. Minna: Molecular genetics of small cell lung carcinoma. Semin Oncol 28, 3-13 (2001) DOI: 10.1053/sonc.2001.25738 DOI: 10.1016/S0093-7754(01)90072-7
210. D. G. Burbee, E. Forgacs, S. Zochbauer-Muller, L. Shivakumar, K. Fong, B. Gao, D. Randle, M. Kondo, A. Virmani, S. Bader, Y. Sekido, F. Latif, S. Milchgrub, S. Toyooka, A. F. Gazdar, M. I. Lerman, E. Zabarovsky, M. White and J. D. Minna: Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 93, 691-699 (2001) DOI: 10.1093/jnci/93.9.691
211. A. M. Senderowicz, I. Viard-Leveugle, S. Veyrenc, L. E. French, C. Brambilla and E. Brambilla: Small-molecule cyclindependent kinase modulators - Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. Oncogene 22, 6609-6620 (2003) DOI: 10.1038/sj.onc.1206954
212. Y. H. Kim, L. Girard, C. P. Giacomini, P. Wang, T. Hernandez-Boussard, R. Tibshirani, J. D. Minna and J. R. Pollack: Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification. Oncogene 25, 130-138 (2006)
213. G. W. Krystal, G. Sulanke and J. Litz: Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 1, 913-922 (2002)
214. D. W. Ball, C. G. Azzoli, S. B. Baylin, D. Chi, S. Dou, H. Donis-Keller, A. Cumaraswamy, M. Borges and B. D. Nelkin: Identification of a human achaete-scute homolog highly expressed in neuroendocrine tumors. Int J Cancer 54, 784-792 (1993)
215. B. A. Westerman, R. H. Breuer, A. Poutsma, A. Chhatta, L. A. Noorduyn, M. G. Koolen, P. E. Postmus, M. A. Blankenstein and C. B. Oudejans: Basic helix-loop-helix transcription factor profiling of lung tumors shows aberrant expression of the proneural gene atonal homolog 1 (ATOH1, HATH1, MATH1) in neuroendocrine tumors. Int J Biol Markers 22, 114-123 (2007)
216. M. Miki, D. W. Ball and R. I. Linnoila: Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. Lung Cancer 75, 58-65 (2012) DOI: 10.1016/j.lungcan.2011.05.019
217. H. Osada, S. Tomida, Y. Yatabe, Y. Tatematsu, T. Takeuchi, H. Murakami, Y. Kondo, Y. Sekido and T. Takahashi: Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res 68, 1647-1655 (2008) DOI: 10.1158/0008-5472.CAN-07-5039
218. R. I. Linnoila, B. Zhao, J. L. DeMayo, B. D. Nelkin, S. B. Baylin, F. J. DeMayo and D. W. Ball: Constitutive achaete-scute homologue-1 promotes airway dysplasia and lung neuroendocrine tumors in transgenic mice. Cancer Res 60, 4005-4009 (2000)
219. K. Hiroshima, A. Iyoda, K. Shibuya, Y. Haga, T. Toyozaki, T. Iizasa, T. Nakayama, T. Fujisawa and H. Ohwada: Genetic alterations in early-stage pulmonary large cell neuroendocrine carcinoma. Cancer 100, 1190-1198 (2004) DOI: 10.1002/cncr.20108
220. R. Ullmann, S. Petzmann, A. Sharma, P. T. Cagle and H. H. Popper: Chromosomal aberrations in a series of large-cell neuroendocrine carcinomas: unexpected divergence from small-cell carcinoma of the lung. Hum Pathol 32, 1059-1063 (2001) DOI: 10.1053/hupa.2001.28248
221. R. Nasgashio, Y. Sato, T. Matsumoto, T. Kageyama, M. Hattori, A. Iyoda, Y. Satoh, S. Ryuge, N. Masuda, S. X. Jiang and M. Saegusa: The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung. Lung Cancer 74, 405-410 (2011) DOI: 10.1016/j.lungcan.2011.04.012
222. S. Petzmann, R. Ullmann, I. Halbwedl and H. H. Popper: Analysis of chromosome-11 aberrations in pulmonary and gastrointestinal carcinoids: an array comparative genomic hybridization-based study. Virchows Arch 445, 151-159 (2004) DOI: 10.1007/s00428-004-1052-y
223. R. S. Macarenco, T. S. Uphoff, H. F. Gilmer, R. B. Jenkins, S. N. Thibodeau, J. E. Lewis, J. R. Molina, P. Yang and M. C. Aubry: Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. Mod Pathol 21, 1168-1175 (2008) DOI: 10.1038/modpathol.2008.113
224. S. W. Han, H. P. Kim, Y. K. Jeon, D. Y. Oh, S. H. Lee, D. W. Kim, S. A. Im, D. H. Chung, D. S. Heo, Y. J. Bang and T. Y. Kim: Mucoepidermoid carcinoma of lung: Potential target of EGFR-directed treatment. Lung Cancer 61, 30-34 (2008) DOI: 10.1016/j.lungcan.2007.11.014
225. I. D. O'Neill: Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene. Lung Cancer 64, 129-130 (2009) DOI: 10.1016/j.lungcan.2009.01.003
226. M. N. Younes, Y. W. Park, Y. D. Yazici, M. Gu, A. A. Santillan, X. Nong, S. Kim, S. A. Jasser, A. K. El-Naggar and J. N. Myers: Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther 5, 2696-2705 (2006) DOI: 10.1158/1535-7163.MCT-05-0228
227. M. C. Aubry, M. C. Heinrich, J. Molina, J. E. Lewis, P. Yang, S. D. Cassivi and C. L. Corless: Primary adenoid cystic carcinoma of the lung: absence of KIT mutations. Cancer 110, 2507-2510 (2007) DOI: 10.1002/cncr.23075
228. R. Dahse, O. Driemel, S. Schwarz, K. Kromeyer-Hauschild, A. Berndt and H. Kosmehl: KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland carcinomas. Oral Oncol 45, 826-829 (2009) DOI: 10.1016/j.oraloncology.2009.01.013
229. J. A. Hu, Y. Li and J. Fang: Effect of ERK inhibitor on pulmonary metastasis of inoculated human adenoid cystic carcinoma cells in nude mice. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109, 117-123 (2010) DOI: 10.1016/j.tripleo.2009.07.052
230. D. J. Dammrich, E. S. Santos and L. E. Raez: Efficacy of sorafenib, a multityrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep 5, 483 (2011) DOI: 10.1186/1752-1947-5-483
231. N. G. Chau, S. J. Hotte, E. X. Chen, S. F. Chin, S. Turner, L. Wang and L. L. Siu: A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol 23, 1562-1570 (2012) DOI: 10.1093/annonc/mdr522
232. M. Persson, Y. Andren, C. A. Moskaluk, H. F. Frierson, Jr., S. L. Cooke, P. A. Futreal, T. Kling, S. Nelander, A. Nordkvist, F. Persson and G. Stenman: Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 51, 805-817 (2012) DOI: 10.1002/gcc.21965
233. A. S. Ho, K. Kannan, D. M. Roy, L. G. Morris, I. Ganly, N. Katabi, D. Ramaswami, L. A. Walsh, S. Eng, J. T. Huse, J. Zhang, I. Dolgalev, K. Huberman, A. Heguy, A. Viale, M. Drobnjak, M. A. Leversha, C. E. Rice, B. Singh, N. G. Iyer, C. R. Leemans, E. Bloemena, R. L. Ferris, R. R. Seethala, B. E. Gross, Y. Liang, R. Sinha, L. Peng, B. J. Raphael, S. Turcan, Y. Gong, N. Schultz, S. Kim, S. Chiosea, J. P. Shah, C. Sander, W. Lee and T. A. Chan: The mutational landscape of adenoid cystic carcinoma. Nat Genet 45, 791-798 (2013) DOI: 10.1038/ng.2643
234. P. J. Stephens, H. R. Davies, Y. Mitani, P. Van Loo, A. Shlien, P. S. Tarpey, E. Papaemmanuil, A. Cheverton, G. R. Bignell, A. P. Butler, J. Gamble, S. Gamble, C. Hardy, J. Hinton, M. Jia, A. Jayakumar, D. Jones, C. Latimer, S. McLaren, D. J. McBride, A. Menzies, L. Mudie, M. Maddison, K. Raine, S. Nik- Zainal, S. O'Meara, J. W. Teague, I. Varela, D. C. Wedge, I. Whitmore, S. M. Lippman, U. McDermott, M. R. Stratton, P. J. Campbell, A. K. El-Naggar and P. A. Futreal: Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 123, 2965-2968 (2013) DOI: 10.1172/JCI67201
235. G. Pelosi, F. Fraggetta, O. Nappi, U. Pastorino, P. Maisonneuve, F. Pasini, A. Iannucci, P. Solli, H. S. Musavinasab, G. De Manzoni, A. Terzi and G. Viale: Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth, and tumor cell motility: a clinicopathologic and immunohistochemical study of 31 cases. Am J Surg Pathol 27, 1203-1215 (2003) DOI: 10.1097/00000478-200309000-00003
236. M. Blaukovitsch, I. Halbwedl, H. Kothmaier, M. Gogg-Kammerer and H. H. Popper: Sarcomatoid carcinomas of the lung - are these histogenetically heterogeneous tumors? Virchows Arch 449, 455-461 (2006) DOI: 10.1007/s00428-006-0256-8
237. A. Italiano, A. B. Cortot, M. Ilie, G. Martel-Planche, T. Fabas, D. Pop, J. Mouroux, V. Hofman, P. Hofman and F. Pedeutour: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer 125, 2479-2482 (2009) DOI: 10.1002/ijc.24610
238. T. W. Fan, A. N. Lane, R. M. Higashi, M. A. Farag, H. Gao, M. Bousamra and D. M. Miller: Altered regulation of metabolic pathways in human lung cancer discerned by C stable isotope-resolved metabolomics (SIRM) Mol Cancer 8, 41 (2009) DOI: 10.1186/1476-4598-8-41
239. P. P. Massion, P. M. Taflan, S. M. Jamshedur Rahman, P. Yildiz, Y. Shyr, M. E. Edgerton, M. D. Westfall, J. R. Roberts, J. A. Pietenpol, D. P. Carbone and A. L. Gonzalez: Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 63, 7113-7121 (2003)
240. P. P. Massion, P. M. Taflan, Y. Shyr, S. M. Rahman, P. Yildiz, B. Shakthour, M. E. Edgerton, M. Ninan, J. J. Andersen and A. L. Gonzalez: Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med 170, 1088-1094 (2004) DOI: 10.1164/rccm.200404-487OC
241. X. Tang, D. Liu, S. Shishodia, N. Ozburn, C. Behrens, J. J. Lee, W. K. Hong, B. B. Aggarwal and Wistuba, II: Nuclear factor-kappaB (NF-kappaB) is frequently expressed in lung cancer and preneoplastic lesions. Cancer 107, 2637-2646 (2006) DOI: 10.1002/cncr.22315
242. J. Shen, C. Behrens, Wistuba, II, L. Feng, J. J. Lee, W. K. Hong and R. Lotan: Identification and validation of differences in protein levels in normal, premalignant, and malignant lung cells and tissues using high-throughput Western Array and immunohistochemistry. Cancer Res 66, 11194-11206 (2006) DOI: 10.1158/0008-5472.CAN-04-1444
243. R. Ullmann, M. Bongiovanni, I. Halbwedl, A. E. Fraire, P. T. Cagle, M. Mori, M. Papotti and H. H. Popper: Is high-grade adenomatous hyperplasia an early bronchioloalveolar adenocarcinoma? J Pathol 201, 371-376 (2003) DOI: 10.1002/path.1460
244. M. Mori, S. K. Rao, H. H. Popper, P. T. Cagle and A. E. Fraire: Atypical adenomatous hyperplasia of the lung: a probable forerunner in the development of adenocarcinoma of the lung. Mod Pathol 14, 72-84 (2001) DOI: 10.1038/modpathol.3880259
245. W. H. Westra, I. O. Baas, R. H. Hruban, F. B. Askin, K. Wilson, G. J. Offerhaus and R. J. Slebos: K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56, 2224-2228 (1996)
246. K. Suzuki, T. Ogura, T. Yokose, K. Nagai, K. Mukai, T. Kodama, Y. Nishiwaki and H. Esumi: Loss of heterozygosity in the tuberous sclerosis gene associated regions in adenocarcinoma of the lung accompanied by multiple atypical adenomatous hyperplasia. Int J Cancer 79, 384-389 (1998) DOI:10.1002/(SICI)1097-0215(1998082 1)79:4〈384::AID-IJC 13〉3.3.CO;2-O DOI:10.1002/(SICI)1097-0215(1998082 1)79:4〈384::AID-IJC13〉3.0.C O;2-5
247. K. Takamochi, T. Ogura, K. Suzuki, H. Kawasaki, Y. Kurashima, T. Yokose, A. Ochiai, K. Nagai, Y. Nishiwaki and H. Esumi: Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. Am J Pathol 159, 1941-1948 (2001) DOI: 10.1016/S0002-9440(10)63041-6
248. H. Awaya, Y. Takeshima, O. Furonaka, N. Kohno and K. Inai: Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung. J Clin Pathol 58, 1076-1080 (2005) DOI: 10.1136/jcp.2004.025585
249. H. Sakamoto, J. Shimizu, Y. Horio, R. Ueda, T. Takahashi, T. Mitsudomi and Y. Yatabe: Disproportionate representation of KRAS gene mutation in atypical adenomatous hyperplasia, but even distribution of EGFR gene mutation from preinvasive to invasive adenocarcinomas. J Pathol 212, 287-294 (2007) DOI: 10.1002/path.2165
250. R. Ullmann, M. Bongiovanni, I. Halbwedl, S. Petzmann, M. Gogg-Kammerer, A. Sapino, M. Papotti, G. Bussolati and H. H. Popper: Bronchiolar columnar cell dysplasia - genetic analysis of a novel preneoplastic lesion of peripheral lung. Virchows Arch 442, 429-436 (2003)
251. W. Pankiewicz, A. Sulewska, W. Niklinska, W. Naumnik, J. Laudanski, J. Niklinski and L. Chyczewski: Immunoexpression of P16INK4a, Rb and TP53 proteins in bronchiolar columnar cell dysplasia (BCCD) in lungs resected due to primary non-small cell lung cancer. Folia Histochem Cytobiol 46, 89-96 (2008) DOI: 10.2478/v10042-008-0013-8
252. E. Stacher, R. Ullmann, I. Halbwedl, M. Gogg-Kammerer, L. Boccon-Gibod, A. G. Nicholson, M. N. Sheppard, L. Carvalho, M. T. Franca, F. Macsweeney, A. Morresi-Hauf and H. H. Popper: Atypical goblet cell hyperplasia in congenital cystic adenomatoid malformation as a possible preneoplasia for pulmonary adenocarcinoma in childhood: A genetic analysis. Hum Pathol 35, 565-570 (2004) DOI: 10.1016/j.humpath.2004.01.008
253. H. Sartelet, M. Decaussin, G. Devouassoux, B. Nawrocki-Raby, P. Y. Brichon, C. Brambilla and E. Brambilla: Expression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1 (Flt-1) and VEGF-R2 (KDR/Flk-1)) in tumorlets and in neuroendocrine cell hyperplasia of the lung. Hum Pathol 35, 1210-1217 (2004) DOI: 10.1016/j.humpath.2004.07.009
254. D. L. Zynger, N. D. Dimov, L. C. Ho, W. B. Laskin and A. V. Yeldandi: Differential expression of neural-cadherin in pulmonary epithelial tumours. Histopathology 52, 348-354 (2008) DOI: 10.1111/j.1365-2559.2007.02952.x
255. L. P. Dehner: Pleuropulmonary blastoma is THE pulmonary blastoma of childhood. Semin Diagn Pathol 11, 144-151 (1994)
256. R. Novak, S. Dasu, D. Agamanolis, W. Herold, J. Malone and J. Waterson: Trisomy 8 is a characteristic finding in pleuropulmonary blastoma. Pediatr Pathol Lab Med 17, 99-103 (1997) DOI: 10.1080/713601257 DOI: 10.3109/15513819709168349 DOI: 10.1080/15513819709168349 DOI: 10.1080/107710497175056
257. M. Barnard, J. Bayani, R. Grant, I. Teshima, P. Thorner and J. Squire: Use of multicolor spectral karyotyping in genetic analysis of pleuropulmonary blastoma. Pediatr Dev Pathol 3, 479-486 (2000) DOI: 10.1007/s100240010094
258. L. Roque, R. Rodrigues, C. Martins, C. Ribeiro, M. J. Ribeiro, A. G. Martins, P. Oliveira and I. Fonseca: Comparative genomic hybridization analysis of a pleuropulmonary blastoma. Cancer Genet Cytogenet 149, 58-62 (2004) DOI: 10.1016/S0165-4608(03)00284-X
259. T. Kusafuka, S. Kuroda, M. Inoue, T. Ara, A. Yoneda, T. Oue, Y. Udatsu, Y. Osugi and A. Okada: P53 gene mutations in pleuropulmonary blastomas. Pediatr Hematol Oncol 19, 117-128 (2002) DOI: 10.1080/08880010252825704
260. I. Slade, C. Bacchelli, H. Davies, A. Murray, F. Abbaszadeh, S. Hanks, R. Barfoot, A. Burke, J. Chisholm, M. Hewitt, H. Jenkinson, D. King, B. Morland, B. Pizer, K. Prescott, A. Saggar, L. Side, H. Traunecker, S. Vaidya, P. Ward, P. A. Futreal, G. Vujanic, A. G. Nicholson, N. Sebire, C. Turnbull, J. R. Priest, K. Pritchard-Jones, R. Houlston, C. Stiller, M. R. Stratton, J. Douglas and N. Rahman: DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome. J Med Genet 48, 273-278 (2011) DOI: 10.1136/jmg.2010.083790
261. M. McGinnis, G. Jacobs, A. el-Naggar and R. W. Redline: Congenital peribronchial myofibroblastic tumor (so-called "congenital leiomyosarcoma") A distinct neonatal lung lesion associated with nonimmune hydrops fetalis. Mod Pathol 6, 487-492 (1993)
262. B. F. Schneider, M. A. Lovell and W. L. Golden: Cytogenetic abnormalities in primary bronchopulmonary leiomyosarcoma of childhood. Cancer Genet Cytogenet 105, 145-151 (1998) DOI: 10.1016/S0165-4608(98)00030-2